Email: cspc@cspc.cn
News
News Center
Mar. 21
2025
SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 18
JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Mar. 13
SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar. 05
JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Feb. 28
SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Feb. 19
VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
